| | | Efficacy (AL change) | Acceptability (dropout rate) | | | Number of studies | Pooled WMD and 95% CI | Heterogeneity value | Number of studies | Pooled OR and 95% CI | Heterogeneity value |
| | Standard analysis | 8 | −0.255 [−0.298, −0.212] | 0.885 | 6 | 0.794 [0.516, 1.222] | 0.320 | | Randomized | 2 | −0.282 [−0.379, −0.185] | 0.664 | 2 | 1.400 [0.722, 2.713] | 1.000 | | Nonrandomized | 6 | −0.248 [−0.296, −0.200] | 0.788 | 4 | 0.510 [0.281, 0.923] | 0.786 | | Prospective | 6 | −0.251 [−0.299, −0.203] | 0.784 | 6 | 0.794 [0.516, 1.222] | 0.320 | | Nested | 2 | −0.272 [−0.371, −0.172] | 0.523 | | | | | Asian | 6 | −0.254 [−0.301, −0.207] | 0.814 | 5 | 0.856 [0.546, 1.341] | 0.330 | | Caucasian | 2 | −0.258 [−0.369, −0.148] | 0.388 | 1 | 0.323 [0.060, 1.726] | 1.000 | | A-Scan | 2 | −0.272 [−0.371, −0.172] | 0.523 | | | | | IOLMaster | 6 | −0.251 [−0.299, −0.203] | 0.784 | 6 | 0.794 [0.516, 1.222] | 0.320 | | OK versus SV | 5 | −0.239 [−0.287, −0.191] | 0.946 | 4 | 0.774 [0.442, 1.355] | 0.303 | | OK versus SC | 1 | −0.320 [−0.499, −0.141] | 1.000 | | | | | PRok versus SV | 1 | −0.320 [−0.517, −0.123] | 1.000 | 1 | 0.794 [0.186, 1.302] | 1.000 | | Tok versus SV | 1 | −0.330 [−0.485, −0.175] | 1.000 | 1 | 1.400 [0.527, 3.718] | 1.000 |
|
|
